Evaluation of the outcome benefit conferred by intensive surveillance strategies in women with early-stage endometrial cancer

Simple item page
dc.contributor.authorKıran, Gürkan
dc.contributor.authorKesterson, Joshua P.
dc.contributor.authorKanis, Margaux Jenna
dc.contributor.authorGroman, Adrienne E.
dc.contributor.authorLele, Shashikant B.
dc.contributor.buuauthorÖzerkan, Kemal
dc.contributor.departmentUludağ Üniversitesi/Tıp Fakültesi/Kadın Hastalıkları ve Doğum Anabilim Dalı.tr_TR
dc.contributor.researcheridAAH-9791-2021tr_TR
dc.contributor.scopusid6603345841tr_TR
dc.date.accessioned2022-03-16T13:16:26Z
dc.date.available2022-03-16T13:16:26Z
dc.date.issued2011-03
dc.description.abstractIntroduction: The optimum follow-up regimen after treatment for early-stage endometrial cancer with curative intent is unknown. The National Comprehensive Cancer Network recommends a physical exam and vaginal cytology every three to six months for two years then at six to 12 month intervals with annual chest X-rays (CXR). However, there is debate as to whether intensive follow-up results in an improvement in outcomes for those with recurrent endometrial cancer. Objective: To determine if intensive surveillance for recurrent cancer in women with early-stage endometrial cancer improves their outcomes. Materials and Methods: The Roswell Park Cancer Institute tumor registry was used to identify patients with Stage I and II endometrial cancer initially diagnosed and treated over an 18-year period, who subsequently recurred. Clinico-pathological variables were abstracted. Patients were divided into two groups, depending on their mode of diagnosis of recurrent cancer: 1) routine screening, or 2) symptomatic. The outcomes between the two groups were compared. Results: Fifty-two patients met inclusion criteria. Twenty-three patients were diagnosed via routine screening methods and 29 were symptomatic at presentation. Groups were equally represented with respect to age, stage, grade, adjuvant therapy, site of recurrence (local, distant), and time to recurrence (p > 0.05). Median survival time was 79 months for those diagnosed during routine screening and 80 months for symptomatic patients (p > 0.05). Conclusion: Pap smear and CXR appear to be of limited utility as the present study has shown that women diagnosed as a result of intensive surveillance did not have a better outcome than those who presented when symptomatic.en_US
dc.identifier.citationKesterson, I. vd. (2011). "Evaluation of the outcome benefit conferred by intensive surveillance strategies in women with early-stage endometrial cancer". Gynecologic Oncology, 121(1), Supplement 1, S11-S12.en_US
dc.identifier.endpageS12tr_TR
dc.identifier.issn0090-8258
dc.identifier.issue10, Supplement 1en_US
dc.identifier.scopus2-s2.0-84898862874tr_TR
dc.identifier.startpageS11tr_TR
dc.identifier.urihttps://doi.org/10.1016/j.ygyno.2010.12.032
dc.identifier.urihttps://www.gynecologiconcology-online.net/article/S0090-8258(10)00915-7/fulltext
dc.identifier.urihttp://hdl.handle.net/11452/25100
dc.identifier.volume121tr_TR
dc.identifier.wos000290292300026tr_TR
dc.indexed.scopusScopusen_US
dc.indexed.wosSCIEen_US
dc.language.isoenen_US
dc.publisherAcademic Press Inc Elsevier Scienceen_US
dc.relation.collaborationYurt içitr_TR
dc.relation.collaborationYurt dışıtr_TR
dc.relation.journalGynaecological Oncologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergitr_TR
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectOncologyen_US
dc.subjectObstetrics & gynecologyen_US
dc.subjectEndometrial canceren_US
dc.subjectSurveillanceen_US
dc.subject.emtreeAdulten_US
dc.subject.emtreeAgeden_US
dc.subject.emtreeArticleen_US
dc.subject.emtreeCancer adjuvant therapyen_US
dc.subject.emtreeCancer centeren_US
dc.subject.emtreeCancer diagnosisen_US
dc.subject.emtreeCancer epidemiologyen_US
dc.subject.emtreeCancer recurrenceen_US
dc.subject.emtreeCancer screeningen_US
dc.subject.emtreeCancer stagingen_US
dc.subject.emtreeClinical evaluationen_US
dc.subject.emtreeClinical featureen_US
dc.subject.emtreeControlled studyen_US
dc.subject.emtreeEarly canceren_US
dc.subject.emtreeEndometrium canceren_US
dc.subject.emtreeFemaleen_US
dc.subject.emtreeFollow upen_US
dc.subject.emtreeHumanen_US
dc.subject.emtreeMajor clinical studyen_US
dc.subject.emtreeMiddle ageden_US
dc.subject.emtreeOutcome assessmenten_US
dc.subject.emtreePapanicolaou testen_US
dc.subject.emtreePatient identificationen_US
dc.subject.emtreeThorax radiographyen_US
dc.subject.emtreeVagina cytologyen_US
dc.subject.emtreeAsymptomatic diseaseen_US
dc.subject.emtreeDisease free survivalen_US
dc.subject.emtreeEarly diagnosisen_US
dc.subject.emtreeEndometrium tumoren_US
dc.subject.emtreeHealth surveyen_US
dc.subject.emtreeKaplan Meier methoden_US
dc.subject.emtreePathologyen_US
dc.subject.emtreeTimeen_US
dc.subject.emtreeTumor recurrenceen_US
dc.subject.emtreeVagina smearen_US
dc.subject.meshAgeden_US
dc.subject.meshAsymptomatic diseasesen_US
dc.subject.meshDisease-free survivalen_US
dc.subject.meshEarly detection of canceren_US
dc.subject.meshEndometrial neoplasmsen_US
dc.subject.meshFemaleen_US
dc.subject.meshHumansen_US
dc.subject.meshKaplan-Meier estimateen_US
dc.subject.meshMiddle ageden_US
dc.subject.meshNeoplasm recurrence, localen_US
dc.subject.meshNeoplasm stagingen_US
dc.subject.meshPopulation surveillanceen_US
dc.subject.meshRadiography, thoracicen_US
dc.subject.meshTime factorsen_US
dc.subject.meshVaginal smearsen_US
dc.subject.scopusFluorodeoxyglucose F 18; Positron Emission Tomography Computed Tomography; Uterine Cervical Neoplasmsen_US
dc.subject.wosOncologyen_US
dc.subject.wosObstetrics & gynecologyen_US
dc.titleEvaluation of the outcome benefit conferred by intensive surveillance strategies in women with early-stage endometrial canceren_US
dc.typeMeeting Abstract
dc.wos.quartileQ1 (Obstetrics & gynecology)en_US
dc.wos.quartileQ2 (Oncology)en_US

Files

License bundle
Now showing 1 - 1 of 1
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

Web of Science
Scopus